Brief: AIM Immunotech Reports Q1 Loss From Operations Of $3.8 Mln
16/05/2022 12:48
May 16 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES
CORPORATE UPDATE
* AIM IMMUNOTECH INC - AS OF MARCH 31, 2022, AIM REPORTED CASH AND CASH
EQUIVALENTS OF $44.5 MILLION
* AIM IMMUNOTECH INC - BASED ON MANAGEMENT'S CURRENT EXPECTATION, COMPANY'S
CASH
RUNWAY IS EXPECTED TO FUND OPERATIONS THROUGH 2023
* AIM IMMUNOTECH INC - NET LOSS FROM OPERATIONS FOR THREE MONTHS MARCH 31,
2022
WAS $3.8 MILLION, OR $0.08 PER SHARE
Source text for Eikon: ID:nGNX4rW1Fz
Further company coverage: AIM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential